An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
REDWOOD CITY, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Coherus BioSciences, Inc. (Nasdaq: CHRS), please note in the Conference Call Information, the start time should be 4:30 p.m. ET, not 5 p.m. ET as previously stated. The corrected release follows:
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its first quarter 2022 financial results will be released after the close of the United States financial markets on Thursday, May 5th, 2022. Starting at 4:30 p.m. ET, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.
After releasing first quarter 2022 financial results, the Company will post them on the Coherus website at https://investors.coherus.com.
Conference Call Information When: Thursday, May 5th, 2022, starting at 4:30 p.m. ET Dial-in: (844) 452-6826 (Toll-Free U.S. and Canada) or (765) 507-2587 (International) Conference ID: 4142969
Please dial-in 15 minutes early to ensure a timely connection to the call. A replay of the webcast will be archived on the Coherus website for 30 days.
coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp
